Engineering extracellular vesicles for Alzheimer's disease: An emerging cell-free approach for earlier diagnosis and treatment.

IF 4.6 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Sabrina Valentina Lazar, Sirjan Mor, David Wang, Leora Goldbloom-Helzner, Kaitlin Clark, Dake Hao, Diana Lee Farmer, Aijun Wang
{"title":"Engineering extracellular vesicles for Alzheimer's disease: An emerging cell-free approach for earlier diagnosis and treatment.","authors":"Sabrina Valentina Lazar,&nbsp;Sirjan Mor,&nbsp;David Wang,&nbsp;Leora Goldbloom-Helzner,&nbsp;Kaitlin Clark,&nbsp;Dake Hao,&nbsp;Diana Lee Farmer,&nbsp;Aijun Wang","doi":"10.1002/wsbm.1541","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting over five million people globally and has no established cure. Current AD-related treatments only alleviate cognitive and behavioral symptoms and do not address disease onset or progression, underlining the unmet need to create an effective, innovative AD therapeutic. Extracellular vesicles (EVs) have emerged as a new class of nanotherapeutics. These secreted, lipid-bound cellular signaling carriers show promise for potential clinical applications for neurodegenerative diseases like AD. Additionally, analyzing contents and characteristics of patient-derived EVs may address the unmet need for earlier AD diagnostic techniques, informing physicians of altered genetic expression or cellular communications specific to healthy and diseased physiological states. There are numerous recent advances in regenerative medicine using EVs and include bioengineering perspectives to modify EVs, target glial cells in neurodegenerative diseases like AD, and potentially use EVs to diagnose and treat AD earlier. This article is categorized under: Neurological Diseases > Biomedical Engineering Neurological Diseases > Molecular and Cellular Physiology Neurological Diseases > Stem Cells and Development.</p>","PeriodicalId":29896,"journal":{"name":"WIREs Mechanisms of Disease","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397584/pdf/nihms-1829487.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"WIREs Mechanisms of Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wsbm.1541","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 5

Abstract

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting over five million people globally and has no established cure. Current AD-related treatments only alleviate cognitive and behavioral symptoms and do not address disease onset or progression, underlining the unmet need to create an effective, innovative AD therapeutic. Extracellular vesicles (EVs) have emerged as a new class of nanotherapeutics. These secreted, lipid-bound cellular signaling carriers show promise for potential clinical applications for neurodegenerative diseases like AD. Additionally, analyzing contents and characteristics of patient-derived EVs may address the unmet need for earlier AD diagnostic techniques, informing physicians of altered genetic expression or cellular communications specific to healthy and diseased physiological states. There are numerous recent advances in regenerative medicine using EVs and include bioengineering perspectives to modify EVs, target glial cells in neurodegenerative diseases like AD, and potentially use EVs to diagnose and treat AD earlier. This article is categorized under: Neurological Diseases > Biomedical Engineering Neurological Diseases > Molecular and Cellular Physiology Neurological Diseases > Stem Cells and Development.

阿尔茨海默病的工程细胞外囊泡:一种用于早期诊断和治疗的新兴无细胞方法。
阿尔茨海默病(AD)是一种使人衰弱的神经退行性疾病,影响着全球500多万人,目前尚无治愈方法。目前的阿尔茨海默病相关治疗仅能缓解认知和行为症状,而不能解决疾病的发病或进展,这表明需要创造一种有效的、创新的阿尔茨海默病治疗方法。细胞外囊泡(EVs)已成为一类新的纳米治疗药物。这些分泌的脂质结合细胞信号载体在阿尔茨海默病等神经退行性疾病的临床应用中显示出潜在的前景。此外,分析患者源性EVs的内容和特征可以解决早期AD诊断技术的未满足需求,告知医生健康和患病生理状态下基因表达或细胞通讯的改变。利用电动汽车的再生医学最近取得了许多进展,包括生物工程角度来修饰电动汽车,靶向神经退行性疾病如阿尔茨海默病的胶质细胞,并有可能使用电动汽车早期诊断和治疗阿尔茨海默病。本文分类为:神经系统疾病>生物医学工程神经系统疾病>分子与细胞生理学神经系统疾病>干细胞与发育。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
WIREs Mechanisms of Disease
WIREs Mechanisms of Disease MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
11.40
自引率
0.00%
发文量
45
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信